Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.38 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoramidic Acid SCHEMBL112691 | 0.95 | DUT (0.47) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| Phosphoramidic Acid SCHEMBL110995 | 0.90 | DUT (0.47) | DUTP2RY2P2RY6P2RY4P2RY14 | |
| Phosphoramidic Acid SCHEMBL111241 | 0.84 | TK1 (0.47) | — | |
| Phosphoramidic Acid SCHEMBL110386 | 0.84 | POLB (0.47) | P2RY2P2RY6P2RY4 | |
| Phosphoramidic Acid SCHEMBL110862 | 0.84 | P2RY2 (0.48) | P2RY2P2RY6P2RY4P2RY14 | |
| Phosphoramidic Acid SCHEMBL110757 | 0.80 | TK1 (0.48) | — | |
| Phosphoramidic Acid SCHEMBL110972 | 0.79 | P2RY2 (0.49) | P2RY2P2RY6P2RY4P2RY14 | |
| Phosphoramidic Acid SCHEMBL109330 | 0.79 | POLB (0.48) | P2RY2P2RY6P2RY4 | |
| Phosphoramidic Acid SCHEMBL111677 | 0.77 | POLB (0.52) | P2RY2P2RY6P2RY4 | |
| SCHEMBL3392998 | 0.76 | DUT (0.53) | DUTP2RY2P2RY6P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-05-03 | — | — | US | disclosed |
| EP-2424874-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125200-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | PNP, TYMP, MTAP | DUT 30/4885P2RY2 1050/4885P2RY6 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.